

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

## OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>KAZIMI A J</u>  (Last) (First) (Middle) 2525 WEST END AVE. SUITE 950  (Street) NASHVILLE TN 37203  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/10/2009	3. Issuer Name and Ticker or Trading Symbol <u>CUMBERLAND PHARMACEUTICALS INC [ CPIX ]</u>  4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chairman and CEO  5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
---	---	---

## Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	5,407,563	D	

Table II - Derivative Securities Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Options	12/18/2001	12/18/2011	Common Stock	6,930	1.63	D	
Options	01/15/2005	01/15/2010	Common Stock	10,600	6.6	D	
Options	12/31/2005	01/15/2010	Common Stock	10,600	6.6	D	
Options	12/31/2006	01/15/2010	Common Stock	10,600	6.6	D	
Options	12/31/2006	06/30/2011	Common Stock	5,000	9.9	D	
Options	12/31/2007	01/15/2010	Common Stock	10,600	6.6	D	
Options	12/31/2007	06/30/2011	Common Stock	5,000	9.9	D	
Options	12/31/2008	01/15/2010	Common Stock	10,600	6.6	D	
Options	12/31/2008	06/30/2011	Common Stock	5,000	9.9	D	
Options	12/31/2008	07/31/2013	Common Stock	7,500	14.3	D	
Options	12/31/2009	06/30/2011	Common Stock	5,000	9.9	D	
Options	12/31/2009	07/31/2013	Common Stock	7,500	14.3	D	
Options	12/31/2009	02/16/2014	Common Stock	7,500	14.3	D	
Options	12/31/2010	07/31/2013	Common Stock	7,500	14.3	D	
Options	12/31/2010	02/16/2014	Common Stock	7,500	14.3	D	
Options	12/31/2011	07/31/2013	Common Stock	7,500	14.3	D	
Options	12/31/2011	02/16/2014	Common Stock	7,500	14.3	D	
Options	12/31/2012	02/16/2014	Common Stock	7,500	14.3	D	

Explanation of Responses:

Remarks:

A.J. Kazimi by: /s/ Jean W. Marstiller, as Attorney-in-fact 08/10/2009

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

**\*\*** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

